1月26日，奥浦迈跌1.60%，成交额6233.60万元。两融数据显示，当日奥浦迈获融资买入额622.55万 元，融资偿还506.21万元，融资净买入116.34万元。截至1月26日，奥浦迈融资融券余额合计7835.33万 元。 融资方面，奥浦迈当日融资买入622.55万元。当前融资余额7835.33万元，占流通市值的1.23%，融资余 额低于近一年20%分位水平，处于低位。 分红方面，奥浦迈A股上市后累计派现1.73亿元。 机构持仓方面，截止2025年9月30日，奥浦迈十大流通股东中，中欧医疗健康混合A（003095）位居第 六大流通股东，持股400.86万股，相比上期增加252.62万股。工银前沿医疗股票A（001717）位居第七 大流通股东，持股330.01万股，相比上期增加40.00万股。中欧医疗创新股票A（006228）位居第九大流 通股东，持股265.16万股，为新进股东。招商医药健康产业股票（000960）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，上海奥浦迈生物科技股份有限公司位于上海市浦东新区紫萍路908弄28号楼，成立日期2013 年11月27日，上市日期2022年9月2日，公司 ...

Group 1 - Aopumai's stock price increased by 1.49% to 56.59 CNY per share, with a trading volume of 124 million CNY and a turnover rate of 1.91%, resulting in a total market capitalization of 6.441 billion CNY [1] - The stock has risen for five consecutive days, accumulating a total increase of 9.86% during this period [1] - Aopumai, established on November 27, 2013, and listed on September 2, 2022, specializes in cell culture products and services, with revenue composition of 87.34% from products, 12.53% from services, and 0.13% from other sources [1] Group 2 - The Qianhai Kaiyuan Fund holds Aopumai as a significant investment, with 58,600 shares representing 1.05% of the fund's net value, making it the sixth-largest holding [2] - The fund has realized a floating profit of approximately 48,600 CNY today and 297,500 CNY during the five-day increase [2] - The Qianhai Kaiyuan Fund, established on June 24, 2016, has a current size of 270 million CNY, with a year-to-date return of 1.59% and a one-year return of 16.5% [2]

工银前沿医疗股票A（001717）成立日期2016年2月3日，最新规模96.36亿。今年以来收益17.03%，同 类排名3002/4189；近一年收益17.03%，同类排名3002/4189；成立以来收益207.9%。 从奥浦迈十大流通股东角度 数据显示，工银瑞信基金旗下1只基金位居奥浦迈十大流通股东。工银前沿医疗股票A（001717）三季 度增持40万股，持有股数330.01万股，占流通股的比例为2.91%。根据测算，今日浮盈赚取约811.82万 元。 1月5日，奥浦迈涨5.02%，截至发稿，报51.46元/股，成交2702.97万元，换手率0.47%，总市值58.57亿 元。 资料显示，上海奥浦迈生物科技股份有限公司位于上海市浦东新区紫萍路908弄28号楼，成立日期2013 年11月27日，上市日期2022年9月2日，公司主营业务涉及从事细胞培养产品与服务。主营业务收入构成 为：产品87.34%，服务12.53%，其他0.13%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投 ...

Group 1 - The core viewpoint of the news is that Aopumai has shown significant growth in revenue and net profit, indicating a positive financial performance [2] - As of December 31, Aopumai's stock price increased by 1.55%, with a trading volume of 33.34 million yuan, and a net financing buy of -1.20 million yuan [1] - The financing balance of Aopumai is 94.02 million yuan, which is 1.69% of its market capitalization, indicating a low financing level compared to the past year [1] Group 2 - For the period from January to September 2025, Aopumai achieved an operating income of 272 million yuan, representing a year-on-year growth of 25.79% [2] - The net profit attributable to the parent company for the same period was 49.43 million yuan, showing an impressive year-on-year increase of 81.48% [2] - Aopumai has distributed a total of 173 million yuan in dividends since its A-share listing [3] Group 3 - As of September 30, 2025, Aopumai had 3,682 shareholders, an increase of 14.63% from the previous period, with an average of 30,838 circulating shares per shareholder, up by 27.96% [2] - Among the top ten circulating shareholders, several institutional investors have increased their holdings, indicating growing institutional interest in Aopumai [3]

Group 1 - The core viewpoint of the news is that Aopumai's stock has shown significant performance with a year-to-date increase of 57.23%, despite a recent decline in the last five and twenty trading days [1] - Aopumai's main business involves cell culture products and services, with revenue composition being 87.34% from products and 12.53% from services [1] - As of September 30, 2025, Aopumai reported a revenue of 272 million yuan, representing a year-on-year growth of 25.79%, and a net profit attributable to shareholders of 49.43 million yuan, which is an increase of 81.48% compared to the previous year [1] Group 2 - Aopumai's stockholders increased to 3,682 as of September 30, 2025, marking a 14.63% rise from the previous period, with an average of 30,838 circulating shares per person, up by 27.96% [1] - The company has distributed a total of 173 million yuan in dividends since its A-share listing [1] - Among the top ten circulating shareholders, notable increases were observed in holdings by institutional investors, such as China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [2]

Core Viewpoint - Aopu Mai's stock price has experienced fluctuations, with a current decline of 2.01% and a year-to-date increase of 59.83%, indicating volatility in the market while showing strong annual growth in revenue and profit [1][2]. Company Overview - Aopu Mai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company is located in Shanghai and specializes in cell culture products and services [1]. - The revenue composition of Aopu Mai is primarily from products (87.34%), followed by services (12.53%) and other sources (0.13%) [1]. Financial Performance - For the period from January to September 2025, Aopu Mai reported a revenue of 272 million yuan, representing a year-on-year growth of 25.79%. The net profit attributable to the parent company was 49.43 million yuan, showing an impressive increase of 81.48% year-on-year [1]. - Since its A-share listing, Aopu Mai has distributed a total of 173 million yuan in dividends [2]. Shareholder Information - As of September 30, 2025, Aopu Mai had 3,682 shareholders, an increase of 14.63% from the previous period. The average number of circulating shares per shareholder rose by 27.96% to 30,838 shares [1]. - Among the top ten circulating shareholders, notable increases were observed in holdings by institutional investors such as China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [2].

11月10日，奥浦迈涨5%，截至发稿，报58.80元/股，成交3087.82万元，换手率0.47%，总市值66.93亿 元。 资料显示，上海奥浦迈生物科技股份有限公司位于上海市浦东新区紫萍路908弄28号楼，成立日期2013 年11月27日，上市日期2022年9月2日，公司主营业务涉及从事细胞培养产品与服务。主营业务收入构成 为：产品87.34%，服务12.53%，其他0.13%。 从奥浦迈十大流通股东角度 数据显示，工银瑞信基金旗下1只基金位居奥浦迈十大流通股东。工银前沿医疗股票A（001717）三季 度增持40万股，持有股数330.01万股，占流通股的比例为2.91%。根据测算，今日浮盈赚取约924.02万 元。 工银前沿医疗股票A（001717）成立日期2016年2月3日，最新规模96.36亿。今年以来收益21.28%，同 类排名2685/4216；近一年收益12.68%，同类排名2778/3917；成立以来收益219.1%。 工银前沿医疗股票A（001717）基金经理为赵蓓。 截至发稿，赵蓓累计任职时间10年361天，现任基金资产总规模172.23亿元，任职期间最佳基金回报 219.1%， 任职期间最 ...

Group 1 - The core point of the news is that Aopumai's stock price has decreased by 5.02%, currently trading at 55.87 CNY per share, with a total market capitalization of 6.359 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with product revenue accounting for 87.34% and service revenue for 12.53% [1] Group 2 - From the perspective of major fund holdings, Guotai Fund has a significant position in Aopumai, with its Guotai National Policy Driven Flexible Allocation Mixed A Fund holding 3,140 shares, representing 0.65% of the fund's net value [2] - The Guotai National Policy Driven Flexible Allocation Mixed A Fund has a total scale of 21.707 million CNY and has achieved a year-to-date return of 3.97% [2] - The fund manager, Deng Shifeng, has a tenure of 17 years and has achieved the best fund return of 167.36% during his management period [2]

Group 1 - The core point of the news is the performance and financial metrics of Aopumai Biotechnology Co., Ltd., which saw a stock price increase of 5.03% to 60.60 CNY per share, with a total market capitalization of 6.898 billion CNY [1] - Aopumai was established on November 27, 2013, and went public on September 2, 2022, focusing on cell culture products and services [1] - The company's revenue composition is primarily from products (87.34%), followed by services (12.53%) and other sources (0.13%) [1] Group 2 - According to data, Aopumai is a significant holding in the Guangfa Balanced Growth Mixed A Fund, which held 1.5283 million shares, accounting for 2.87% of the fund's net value, ranking as the ninth largest holding [2] - The Guangfa Balanced Growth Mixed A Fund has achieved a year-to-date return of 50.18%, ranking 1148 out of 8154 in its category, and a one-year return of 48.28%, ranking 1193 out of 8046 [2] - The fund manager, Yang Dong, has been in position for 4 years and 123 days, with a total asset scale of 23.666 billion CNY and a best fund return of 103.21% during his tenure [2]

Core Viewpoint - Aopumai, a leading company in the cell culture products and services sector in China, has shown significant growth potential despite its current lower ranking in revenue and profit compared to industry leaders [1][2]. Group 1: Company Overview - Aopumai was established on November 27, 2013, and was listed on the Shanghai Stock Exchange on September 2, 2022, with its headquarters in Shanghai [1]. - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category, and has a comprehensive industry chain and technological research advantages [1]. Group 2: Financial Performance - For Q3 2025, Aopumai reported revenue of 272 million yuan, ranking 28th out of 34 in the industry, significantly lower than the top competitors [2]. - The revenue composition includes product revenue of 155 million yuan (87.34%), service revenue of 22.27 million yuan (12.53%), and other revenue of 0.233 million yuan (0.13%) [2]. - The net profit for the same period was 49.06 million yuan, ranking 18th in the industry, again trailing behind leading companies [2]. Group 3: Financial Ratios - Aopumai's debt-to-asset ratio stood at 7.59% in Q3 2025, slightly up from 7.00% year-on-year, but well below the industry average of 26.88%, indicating strong solvency [3]. - The gross profit margin was reported at 54.57%, down from 57.45% year-on-year and below the industry average of 70.17%, suggesting room for improvement in profitability [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 14.63% to 3,682, with an average holding of 30,800 shares, up 27.96% [5]. - Notable changes among the top ten circulating shareholders include increases in holdings by several funds, indicating growing investor interest [5]. Group 5: Future Outlook - Aopumai is expected to see revenue growth in the coming years, with projected revenues of 379 million yuan, 473 million yuan, and 586 million yuan for 2025, 2026, and 2027, respectively [5]. - The net profit forecasts for the same years are 87 million yuan, 107 million yuan, and 134 million yuan, reflecting a positive growth trajectory [5].